Fruit of Styphnolobium japonicum (L.) Schott (syn. Sophora japonica L.) afforded the flavonoids known for this plant genistein, sophoricoside, genistin, genistein 4′-O-α-L-rhamnopyranoside, and kaempferol 3-O-sophoroside and the new genistein 4′-O-rutinoside [genistein 4′-O-(6′′-α-L-rhamnopyranosyl)-β-D-glucopyranoside], which was isolated for the first time. The chemical structures of the isolated phenolic compounds were studied using UV, 1H and 13C NMR spectroscopy; mass spectrometry; and chemical transformations.
Medical deepfakes are AI-generated synthetic medical images that convincingly replicate real scans. They compromise diagnostic integrity and emphasize the need for dependable algorithmic protections in AI-driven medical imaging. Building upon our earlier conference paper, "A Hybrid Approach for Medical Deepfake Detection Using Depth-Wise Convolutions in Vision Transformer and Frequency Domain Analysis [1]" this work extends and refines that framework to develop a more robust medical deepfake detection model. The proposed hybrid architecture incorporates a modified ConvNeXtV2-Tiny backbone augmented with a Triplet Attention Mechanism, specifically designed to enhance spatial, channel-wise, and cross-dimensional feature interactions. This design enables the model to detect subtle forensic inconsistencies often overlooked by traditional CNN and transformer architectures. Evaluated on the ISIC 2019 skin cancer dataset comprising real images along with StyleGAN-and diffusion-generated fakes, the model achieves 96.3 % accuracy under 5-fold cross-validation. Experimental results demonstrate consistent improvements across accuracy, precision, recall, F1-score, and AUC, surpassing existing medical deepfake detection approaches. Despite the limited dataset size, the model exhibits strong generalization, supported by its multimodal input representation and attention-guided feature refinement.
A homonymous visual field defect (homonymous hemianopia) is the most common visual dysfunction after a cerebrovascular accident and is associated with involvement of the postchiasmatic pathways (usually the optic radiation or peristriate cortex). Patients with hemianopia experience difficulties with daily activities, such as navigation, visual search, recognition of people and objects, and reading. This review presents current data on use and effectiveness of various non-drug methods for neurorehabilitation in patients with homonymous visual field defects, including approaches for compensation, replacement, and recovery (trainings for restoring vision, stimulus response practices, systematic training of eye movement, use of immersive technologies, multisensory and transcranial non-invasive stimulation, etc.), as well as analyzes the available scientific data on the neurophysiological basis of recovery of patients with hemianopia after a cerebrovascular accident. Activation of neuroplasticity mechanisms underlying rehabilitation in homonymous hemianopia after stroke, and targeted management of cortical reorganization processes, help achieve the best recovery of visual functions.
BACKGROUND. Resistance and intolerance to treatment for Ph+ chronic myeloid leukemia (CML) after failure of imatinib therapy remain an issue in clinical oncohematology. Vamotinib (former name PF-114) is a domestic innovative third-generation BCR::ABL1-tyrosine kinase inhibitor (TKI). Previous pre-clinical studies and a phase 1 clinical trial demonstrated the efficacy and safety of this drug in Ph+ CML therapy, also in patients with resistance and/or intolerance to second-generation TKIs as well as with T315I mutation. AIM. To study vamotinib efficacy and safety profile compared with high-dose imatinib in terms of the major molecular response (MMR) rate after 12-month treatment in CML patients in chronic phase (CP). MATERIALS & METHODS. The present phase 3 trial is prospective, randomized, open-label, multi-center, and international (Russia and India). CML patients in CP with 400 mg or 600 mg imatinib resistance were randomized into the high-dose imatinib (600 mg or 800 mg) and 300 mg vamotinib groups. After imatinib therapy failure, patients could switch to vamotinib treatment. RESULTS. The trial enrolled 180 patients (89 in vamotinib and 91 in imatinib groups); interim analysis was carried out after 12 months of therapy. The primary endpoint was reached: superiority of vamotinib was demonstrated in terms of MMR rate (47.2 % vs. 12.1 % on imatinib; p < 0.001). Vamotinib is distinguished by a favorable safety profile; the number of patients with adverse events (AEs) grade 3/4 was 11 in vamotinib vs. 8 in imatinib groups. The most prevalent AE on vamotinib therapy was cutaneous toxicity; hematologic toxicity was not characteristic, no vascular occlusions were observed. CONCLUSION. The interim analysis after 12 months therapy with vamotinib showed that it holds promise for the treatment of CP CML patients with 400 mg or 600 mg imatinib resistance.
HPLC techniques for quantitative determination of myricitrin (myricetin-3-O-α-L-rhamnopyranoside) in extracts from leaves of common myrtle (Myrtus communis L.) were developed. The contents of myricitrin in tincture, infusion, and thick extract of myrtle leaves were determined as 0.68 ± 0.02; 0.17 ± 0.01 and 12.75 ± 0.05
